id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2025-P-2170-0009,FDA,FDA-2025-P-2170,Response Letter,Other,Letter(s),2025-12-30T05:00:00Z,2025,12,2025-12-30T05:00:00Z,,2025-12-31T00:38:33Z,,0,0,09000064b91134cf
FDA-2025-P-2170-0008,FDA,FDA-2025-P-2170,"Completeness Assessment Correspondence from FDA CDER to Lachman Consulting Services, Inc.",Other,Assessment Document or Analysis,2025-07-28T04:00:00Z,2025,7,2025-07-28T04:00:00Z,,2025-07-28T21:32:07Z,,0,0,09000064b8eb1469
FDA-2025-P-2170-0004,FDA,FDA-2025-P-2170,Attachment 2 - Prescribing Information for Vyndaqel and Vyndamax,Supporting & Related Material,Background Material,2025-07-07T04:00:00Z,2025,7,,,2025-07-08T02:20:51Z,,0,0,09000064b8e5879e
FDA-2025-P-2170-0001,FDA,FDA-2025-P-2170,"Suitability Petition from Lachman Consulting Services, Inc.",Other,Petition(s),2025-07-07T04:00:00Z,2025,7,2025-07-07T04:00:00Z,,2026-02-27T01:33:39Z,,0,0,09000064b8e57252
FDA-2025-P-2170-0002,FDA,FDA-2025-P-2170,"Acknowledgment Letter from FDA DMB to Lachman Consulting Services, Inc.",Other,Acknowledgement Letter/Receipt,2025-07-07T04:00:00Z,2025,7,2025-07-07T04:00:00Z,,2025-07-08T02:20:35Z,,0,0,09000064b8e57254
FDA-2025-P-2170-0003,FDA,FDA-2025-P-2170,Attachment 1 - Orange Book - Approved Drug Products with Therapeutic Equivalence Evaluations,Supporting & Related Material,Background Material,2025-07-07T04:00:00Z,2025,7,,,2025-07-08T02:20:44Z,,0,0,09000064b8e5879d
FDA-2025-P-2170-0006,FDA,FDA-2025-P-2170,Attachment 4 - Hereditary Transthyretin Amyloidosis,Supporting & Related Material,Background Material,2025-07-07T04:00:00Z,2025,7,,,2025-07-08T02:21:09Z,,0,0,09000064b8e587a0
FDA-2025-P-2170-0005,FDA,FDA-2025-P-2170,Attachment 3 - Prescribing Information for Tafamidis Tablets,Supporting & Related Material,Background Material,2025-07-07T04:00:00Z,2025,7,,,2025-07-08T02:21:00Z,,0,0,09000064b8e5879f
FDA-2025-P-2170-0007,FDA,FDA-2025-P-2170,Attachment 5 - Highlights of Prescribing Information for Vyndaqel and Vyndamax,Supporting & Related Material,Background Material,2025-07-07T04:00:00Z,2025,7,,,2025-07-08T02:21:18Z,,0,0,09000064b8e587a1